Search

Displaying results 1601 - 1610 of 7498 in total
  1. Drug

    Eszopiclone

    go.drugbank.com/drugs/DB00402
    ApprovedInvestigational

    Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. … Eszopiclone was initially approved by the FDA in 2004.[L6769]

  2. Drug

    Roxadustat

    go.drugbank.com/drugs/DB04847
    ApprovedInvestigational

    It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels. … [A245393] Roxadustat was first approved by the European Commission in August 2021.[L40323]

  3. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calcium crystal formation. … [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1.

  4. Drug

    Tavaborole

    go.drugbank.com/drugs/DB09041
    Approved

    Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). … Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes

  5. Drug

    DL-dimyristoylphosphatidylglycerol

    go.drugbank.com/drugs/DB11284
    Approved

    DL-dimyristoylphosphatidylglycerol is a phospholipid used in commercially available pharmaceutical preparations to solubilize drugs for injection.

  6. Drug

    Normethadone

    go.drugbank.com/drugs/DB11609
    ApprovedIllicit

    It is marketed in Canada by Valeant under the tradename Cophylac.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.

  8. Drug

    Terfenadine

    go.drugbank.com/drugs/DB00342
    ApprovedWithdrawn

    In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation.

    Categories: Histamine H1 Antagonists, Non-Sedating
  9. Drug

    Tetrabenazine

    go.drugbank.com/drugs/DB04844
    Approved

    A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … FDA approved on August 15, 2008.

  10. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.

    Mixtures: NEUMOLEX® NFCategories: Histamine H1 Antagonists, Non-Sedating